|
NSD2 inhibition as a therapeutic approach for treatment-induced neuroendocrine prostate cancer. |
|
|
Employment - Astellas Pharma (I); K36 therapeutics |
Stock and Other Ownership Interests - Astellas Pharma (I); K36 therapeutics |
Consulting or Advisory Role - Third Rock Ventures |
Patents, Royalties, Other Intellectual Property - Astellas Pharma (I); Ikena Oncology |
|
|
Employment - J Erin Flynt |
Stock and Other Ownership Interests - J Erin Flynt |
Patents, Royalties, Other Intellectual Property - J Erin Flynt |
|
|
No Relationships to Disclose |
|
|
|
Stock and Other Ownership Interests - Luis Soares |
Consulting or Advisory Role - Luis Soares |
|
|
Consulting or Advisory Role - Eva Corey |
Research Funding - Eva Corey |
|
|
Employment - Terry Connolly |
Leadership - Terry Connolly |
Stock and Other Ownership Interests - Terry Connolly |
Patents, Royalties, Other Intellectual Property - Terry Connolly |
|
|
Employment - Benjamin Winograd |
Leadership - Benjamin Winograd |
Stock and Other Ownership Interests - Benjamin Winograd |
Patents, Royalties, Other Intellectual Property - Bejamin Winograd |